
Philip Morris has raised its bid for British drugmaker Vectura to 165 pence (US$2.29) per share, the tobacco company stated on Sunday, August 8.
“The PMI (Philip Morris International) increased offer values the entire issued and to be issued ordinary share capital of Vectura at approximately 1.02 billion pounds ($1.41 billion),” it wrote in an emailed statement to Reuters.
The latest offer represents a premium of approximately 10 pence per share to a rival offer of 155 pence a share by US-based Carlyle Group announced on Friday.
Carlyle offered to buy Vectura for about £958 million (US$1.3 billion). Vectura, which makes respiratory treatments, had stated on Friday that it was backing Carlyle’s offer and withdrawing its recommendation for Philip Morris’ proposal, adding that it might be better positioned under Carlyle’s ownership.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Withdraws Case Against Microsoft-Activision Merger, Citing Public Interest
May 23, 2025 by
CPI
Charter to Acquire Cox Communications in $35 Billion Deal
May 22, 2025 by
CPI
FTC Targets Media Watchdog Over Alleged Collusion Against Musk’s X
May 22, 2025 by
CPI
FTC Drops Antitrust Case Accusing Pepsi of Squeezing Small Retailers
May 22, 2025 by
CPI
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros